Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now?

0
66

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood’s ARK increased its stake in the company by 8% in the fourth quarter, entering 2026 with a $10.5 million position.

Crispr Therapeutics Ag (NASDAQ:CRSP) has the first-mover advantage in the gene editing and gene therapy industries with its CRISPR-based treatment approved by the FDA. Its CASGEVY therapy for severe sickle cell disease and beta-thalassemia is already generating revenue through its partnership with Vertex. Crispr Therapeutics Ag (NASDAQ:CRSP) has a strong pipeline and an advanced technology to edit cells both outside the body.

Crispr Therapeutics Ag (NASDAQ:CRSP) saw an increase in hedge fund sentiment in the fourth quarter, as 32 funds ended the…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here